Ebronucimab vs Recaticimab

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Atherosclerotic Cardiovascular Disease

Shared mechanism: PCSK9 · full Atherosclerotic Cardiovascular Disease pipeline

Ebronucimab

Marketed by Hubei Jumpcan Pharmaceutical and partners

Phase 3 in Atherosclerotic Cardiovascular Diseasemonoclonal antibody
Partial signal

NCT05255094 · Phase 3 · completed

The trial was randomized, quadruple-blind, placebo-controlled, and enrolled 464 participants, providing a strong experimental design. Its primary endpoint was a laboratory lipid measure rather than a hard clinical outcome. The registry record gives no statistical test for the primary comparison; the key result shown reports it from the cited source.

Reported efficacy

Percentage change from baseline of serum LDL-C level (At week 12): LDL-C percentage change from baseline to week 12 vs placebo: 450 mg Q4W -59.13 percentage points (95% CI -64.10 to -54.15, adjusted p<0.0001); 150 mg Q2W -60.43 percentage points (95% CI -65.45 to -55.416, adjusted p<0.0001). (met)

Result source: NCT05255094

Recaticimab

Marketed by Jiangsu Hengrui Pharmaceuticals

Phase 3 in Atherosclerotic Cardiovascular Diseasemonoclonal antibody
Reliable signal

NCT04849000 · Phase 3 · completed

This was a randomized, quadruple-blind, placebo-controlled trial with 709 participants, using percentage change in LDL cholesterol as the primary measure. The sponsor reports statistically significant LDL reductions of 45 to 53 percentage points versus placebo across all three dosing regimens.

Next expected readout: June 2027 · NCT07373847 (registry estimate)

Reported efficacy

12 weeks Percentage change in serum LDL-C levels from baseline.: Change in LDL-C from baseline at Week 12: -54.4% recaticimab vs -4.5% placebo; treatment difference -49.8 percentage points (95% CI -55.8 to -43.9), P<0.0001 (met)

Result source: NCT04844125

Results for Atherosclerotic Cardiovascular Disease

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointEbronucimabRecaticimab
LDL-C, % change—Not posted · NCT05260411-51% vs 2%a−53 vs placebo450mg Q12W · wk 24NCT04885218
3 other results
  • -59% vs 0.4% 300mg Q8W · wk 24 · Phase 3 · primary NCT04885218
  • -62% vs 0% 150mg Q4W · wk 24 · Phase 3 · primary NCT04885218
  • -54.4% vs -4.5% wk 12 · Phase 3 · primary NCT04844125
Non-HDL-C, % change—Not posted · NCT05260411—Not posted · NCT04844125
ApoB, % change—Not posted · NCT05260411—Not posted · NCT04844125
Lp(a), % change—Not posted · NCT05260411—Not posted · NCT04844125
3-point MACE (% with event)—Not posted · NCT05260411—Not posted · NCT04844125

LDL-C, % change

Ebronucimab
—Not posted · NCT05260411
Recaticimab
-51% vs 2%a−53 vs placebo450mg Q12W · wk 24NCT04885218
3 other results
  • -59% vs 0.4% 300mg Q8W · wk 24 · Phase 3 · primary NCT04885218
  • -62% vs 0% 150mg Q4W · wk 24 · Phase 3 · primary NCT04885218
  • -54.4% vs -4.5% wk 12 · Phase 3 · primary NCT04844125

Non-HDL-C, % change

Ebronucimab
—Not posted · NCT05260411
Recaticimab
—Not posted · NCT04844125

ApoB, % change

Ebronucimab
—Not posted · NCT05260411
Recaticimab
—Not posted · NCT04844125

Lp(a), % change

Ebronucimab
—Not posted · NCT05260411
Recaticimab
—Not posted · NCT04844125

3-point MACE (% with event)

Ebronucimab
—Not posted · NCT05260411
Recaticimab
—Not posted · NCT04844125
  1. a From a reviewed publication or company release; CT.gov has no posted result for this endpoint.
  2. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  3. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
1 other shared endpoint

Coverage. Ebronucimab: 1 of 1 rows · Recaticimab: 1 of 1 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricEbronucimabRecaticimab
LDL-C
percent change · % of baseline
No placebo or comparator arm
-59.13% @ 12wk450 mg Q4Wa,b,c,d
NCT05255094 · Phase 3 · sponsor-reported, not registry data
show 1 more dose
-60.43% @ 12wk150 mg Q2W
NCT05255094 · Phase 3 · sponsor-reported, not registry data
-45%450 mg Q12Wa,b,c,d
NCT04849000 · Phase 3 · sponsor-reported, not registry data
show 2 more doses
-52.8%300 mg Q8W
NCT04849000 · Phase 3 · sponsor-reported, not registry data
-49.6%150 mg Q4W
NCT04849000 · Phase 3 · sponsor-reported, not registry data

Notes

  1. aThis study reports multiple eligible drug arms; no representative arm has been reviewed.
  2. bPopulation comparability has not been reviewed for both studies.
  3. cTreatment context has not been resolved for both arms.
  4. dThe assessment timepoint is not available for both results.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

Recaticimab

LDL-C -51% vs 2% placebo @ 24wk450mg Q12W
percent change · % of baseline
NCT04885218 · Phase 3 · sponsor-reported, not registry data
show 3 more results
-59% vs 0.4% placebo @ 24wk300mg Q8W
NCT04885218 · Phase 3 · sponsor-reported, not registry data
-62% vs 0% placebo @ 24wk150mg Q4W
NCT04885218 · Phase 3 · sponsor-reported, not registry data
-54.4% vs -4.5% placebo @ 12wk
NCT04844125 · Phase 3 · sponsor-reported, not registry data

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Ebronucimab's landscape · Recaticimab's landscape